Last reviewed · How we verify
LVGN6051
At a glance
| Generic name | LVGN6051 |
|---|---|
| Sponsor | Lyvgen Biopharma Holdings Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (PHASE1)
- Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy (PHASE1)
- Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy (PHASE1)
- A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma (PHASE1, PHASE2)
- A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) (PHASE2)
- Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LVGN6051 CI brief — competitive landscape report
- LVGN6051 updates RSS · CI watch RSS
- Lyvgen Biopharma Holdings Limited portfolio CI